CELL INTELLIGENCE · 肿瘤细胞治疗研究

急性髓系白血病双特异性抗体：从骨髓免疫龛到临床转化

Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation.

皮肤 T 细胞淋巴瘤的新兴治疗策略：临床试验综合综述

Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials.

2020-2025 年期间为 CTCL 带来了有意义的治疗进展，包括新的 FDA 批准、突破性疗法认定以及细胞疗法的出现。未来的发展应优先将患者报告结局作为共同主要终点、前瞻性生物标志物验证，以及具有非重叠毒性特征的联合策略。

战略创新：应对急性髓系白血病免疫治疗的挑战

Strategic innovations: Tackling challenges of immunotherapy in acute myeloid leukemia.

多发性骨髓瘤的新型免疫靶点：生物学意义与治疗潜力

Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.

当前抗骨髓瘤 CAR-T 细胞：新型靶点与方法

Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.

高危 MCL：识别与治疗

High-risk MCL: recognition and treatment.

分泌抗 CD33/抗 CD3 双靶向抗体的 CD70 CAR-T 细胞克服 AML 中的抗原异质性

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML.

抗肿瘤 CAR-T 细胞筛选平台：被召唤者众，被选中者寡

Antitumor CAR T-cell Screening Platform: Many Are Called, but Few Are Chosen.

靶向 CD70 的异体 CAR-T 细胞用于治疗肾细胞癌的临床前开发与评价

Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma.

2022 年套细胞淋巴瘤：分子发病机制、风险分层、临床策略及当前与新型治疗的综合更新

Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatment